BCL2L1 and neoplasm: For this purpose, a new group of Alb-R26Met tumor-bearing mice was generated to constitute cohorts treated with a combinatorial regiment of anti-PDL1+anti-CTLA4 together with either Decitabine or MEK+BCL-XL blockage (Figure 5A; Tables S7 and S8).